Sanofi-Aventis: enoxaparin reduces bleeding after PCI treatment

By Lisa Kerner

Charlotte, N.C., Sept. 7 - The New England Journal of Medicine published Sanofi-Aventis Group's international Steeple trial demonstrating that major and minor bleeding after percutanous coronary intervention (PCI) or coronary angioplasty was 31% less following a single intravenous bolus of enoxaparin of 0.5 mg/kg compared to unfractionated heparin (UFH).

In addition, both studied doses of enoxaparin (0.5 mg/kg and 0.75 mg/kg) led to more predictable anticoagulation levels and similar efficacy than unfractionated heparin in patients undergoing elective PCI or coronary angioplasty.

The study was conducted in 3,528 patients at 124 sites in nine countries.

"UFH has been the standard anticoagulant used during PCI procedures, and the Steeple trial was the first large scale, randomized, controlled, open-label trial to compare intravenous enoxaparin to UFH during PCI," said Gilles Montalescot, chairman of the trial steering committee, in a news release.

Sanofi-Aventis is a Paris-based pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.